Arrowhead Pharmaceuticals, Inc. (ARWR) Trading Up -5.4%
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) was up 5.4% during trading on Friday . The company traded as high as $3.42 and last traded at $3.13. Approximately 974,820 shares changed hands during trading, a decline of 2% from the average daily volume of 999,697 shares. The stock had previously closed at $3.31.
A number of equities research analysts recently commented on ARWR shares. ValuEngine lowered Arrowhead Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Piper Jaffray Companies restated a “hold” rating and set a $2.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Friday, July 28th. Finally, Jefferies Group LLC restated a “hold” rating and set a $2.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Friday, August 4th. One research analyst has rated the stock with a sell rating and five have assigned a hold rating to the company. The company has an average rating of “Hold” and an average target price of $1.80.
The company has a 50 day moving average price of $2.18 and a 200-day moving average price of $1.85. The firm’s market cap is $232.54 million.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.06. Arrowhead Pharmaceuticals had a negative net margin of 201.84% and a negative return on equity of 46.73%. The business had revenue of $9.34 million during the quarter, compared to the consensus estimate of $5.29 million. Equities research analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post ($0.42) earnings per share for the current year.
Several large investors have recently made changes to their positions in ARWR. LMR Partners LLP acquired a new position in shares of Arrowhead Pharmaceuticals during the second quarter worth $467,000. Wells Fargo & Company MN increased its holdings in shares of Arrowhead Pharmaceuticals by 144.8% during the first quarter. Wells Fargo & Company MN now owns 150,346 shares of the biotechnology company’s stock worth $278,000 after buying an additional 88,933 shares in the last quarter. SG Americas Securities LLC increased its holdings in shares of Arrowhead Pharmaceuticals by 287.9% during the first quarter. SG Americas Securities LLC now owns 100,747 shares of the biotechnology company’s stock worth $186,000 after buying an additional 74,776 shares in the last quarter. UBS Asset Management Americas Inc. increased its holdings in shares of Arrowhead Pharmaceuticals by 414.7% during the first quarter. UBS Asset Management Americas Inc. now owns 66,400 shares of the biotechnology company’s stock worth $123,000 after buying an additional 53,500 shares in the last quarter. Finally, Virtu KCG Holdings LLC increased its holdings in shares of Arrowhead Pharmaceuticals by 115.6% during the second quarter. Virtu KCG Holdings LLC now owns 99,267 shares of the biotechnology company’s stock worth $161,000 after buying an additional 53,215 shares in the last quarter. Institutional investors own 20.63% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Arrowhead Pharmaceuticals, Inc. (ARWR) Trading Up -5.4%” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/09/10/arrowhead-pharmaceuticals-inc-arwr-trading-up-5-4.html.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.
Receive News & Stock Ratings for Arrowhead Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.